On Monday, November 30, 2020, HAE Canada is holding its virtual Annual General Meeting at 7:00 p.m. ET.
All HAE Canada members are welcome to attend. An invitation was emailed to members containing details, registration information and the necessary AGM documents (the Agenda, nomination & proxy forms, etc.). Please note, to attend the meeting, you must register no later than 12:00 noon EST, Friday, November 27, 2020.
If you did not receive your invitation, please contact Daphne at office@haecanada.org and she will happily email your invitation to you.
Nomination Forms for a position on the Board of Directors must be submitted by November 12 at 5:00 p.m. ET. The invitation contains an online Nomination Form & a printable PDF version. If you need the PDF version emailed directly to you, please send your request to office@haecanada.org.
If you are not able to attend the meeting, we ask that you please fill out the proxy form (included in the AGM invitation) by Thursday, November 26 so we are able to achieve quorum at the meeting. Thank You.
The 2020 National Report Card
Three years ago our membership filled out our survey that provided data for our National Report Card. It’s time to update this information.
In September, we will email our members links to our survey. Completing this survey will not only provide HAE Canada with important information that will be used to advocate for access to treatments, it will also give members a chance to win a travel grant to attend the next HAEi Global Conference.
Latest News
TAKHZYRO: One Step Closer
Amazing news! Canadian HAE patients are one step closer to gaining equitable access to the new treatment, TAKHZYRO! After months of negotiations, Takeda Canada announced it has completed
Terrific News for HAE Patients in Quebec
We have some exciting news to share! We are pleased to let everyone know the Institut national d’excellence en santé et en services sociaux (INESSS) has reevaluated lanadelumab
Canada Won the 2020 HAE Global Walk
Thank you to the amazing HAE Community here in Canada - Canada won the Virtual 2020 HAE Global Walk; an annual event organized by the HAE International team.
Great News!
HAEGARDA and TAKHZYRO are now available in Canada. Please talk to your HAE specialist about access. Thank you Canadian Blood Services (CBS) for a very collaborative, informative and
HAE Day 2020
For HAE Day 2020, HAE Canada wants to celebrate! To honour the day we have two BIG announcements: 1) Our website received a facelift! We hope our
Virtual HAE Global Walk
It’s time, once again, for HAE Canada to please ask you to take out your walking shoes and participate in the virtual HAE Global Walk arranged by HAE
HAE Canada’s message on COVID-19
HAE Canada continues to remain focused on the health and well-being of patients with hereditary angioedema, and other related angioedema, in Canada. We would like to share what
HAEGARDA is available in Quebec
We are thrilled to let the HAE community know that HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) is now available to HAE patients in Quebec. HAEGARDA is a subcutaneous
Support Family Testing
Give valuable insights in HAE science
Hereditary Angioedema (HAE) is a hereditary disorder. It is therefore very important to have other family members tested. To help you in this process HAE International has developed two documents for patients. You can download the documents below:
